OncoImmunology

期刊简介：Tumor immunology deals with the natural or therapy-induced recognition of cancers, as well as with the intricate interplay between oncogenesis, inflammation and immunosurveillance. We now create a new, high-profile journal, OncoImmunology, that specifically deals with tumor immunology. Recent progress has allowed for the first clinical demonstration (and FDA approval) of anticancer immunotherapies. There is also an ever growing suspicion that - unexpectedly - many of the currently used chemotherapeutic agents depend in their efficacy on the active contribution of immune effectors. To use a drastic metaphor, oncologists who applied successful chemotherapeutic (or radiotherapeutic) regimens have taken advantage of the immune system's capacity to recognize tumor-specific or tumor-associated antigens and to control cancer (stem) cell growth, without being aware of the invisible helping hands. As a result, immunological biomarkers are becoming ever more important to determine the prognosis of cancers and to predict the efficacy of chemotherapies. There is also a strong rationale in favor of combining conventional anticancer therapies with immunotherapies.OncoImmunology will accept high-profile submissions in the fundamental, translational and clinical areas of tumor immunology. Submissions dealing with solid or hematological cancers, inflammation, innate and acquired immune responses will be welcome.

【译文】肿瘤免疫学涉及癌症的自然或治疗诱导的识别，以及肿瘤发生、炎症和免疫监视之间的复杂相互作用。我们现在创建了一本新的、高调的期刊《肿瘤免疫学》，专门处理肿瘤免疫学。最近的进展已经允许进行首次临床示范（以及FDA批准）抗癌免疫疗法。还有越来越多的怀疑——出乎意料的是——目前使用的许多化疗药物的有效性依赖于免疫效应子的积极贡献。用一个极端的比喻来说，应用成功的化疗（或放疗）方案的肿瘤学家已经利用了免疫系统识别肿瘤特异性或肿瘤相关抗原以及控制癌症（干细胞）生长的能力，而没有意识到无形中的帮助之手。因此，免疫生物标志物在确定癌症预后和预测化疗效果方面变得越来越重要。将传统抗癌疗法与免疫疗法相结合也有很强的理论依据。《肿瘤免疫学》将接受肿瘤免疫学基础、转化和临床领域的高调投稿。欢迎提交涉及实体瘤或血液系统癌症、炎症、先天性和适应性免疫反应的稿件。